NASDAQ:SCYX SCYNEXIS Q3 2026 Earnings Report $4.92 +0.09 (+1.76%) As of 12:14 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast SCYNEXIS EPS ResultsActual EPSN/AConsensus EPS -$0.72Beat/MissN/AOne Year Ago EPSN/ASCYNEXIS Revenue ResultsActual RevenueN/AExpected Revenue$0.15 millionBeat/MissN/AYoY Revenue GrowthN/ASCYNEXIS Announcement DetailsQuarterQ3 2026Date11/4/2026TimeBefore Market OpensConference Call DateTuesday, November 10, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile SCYNEXIS Earnings HeadlinesSCYNEXIS (NASDAQ:SCYX) Shares Cross Above Fifty Day Moving Average - What's Next?October 7 at 3:01 AM | americanbankingnews.comSCYNEXIS Reports Favorable Phase 1 Results For ADPKD DrugOctober 6 at 12:34 PM | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...October 6 at 12:34 PM | markets.businessinsider.comSCYNEXIS Announces Positive Phase 1 Results for SCY-770 in ADPKD, Supports Planned Phase 2 Study in Q4 2026October 6 at 8:10 AM | quiverquant.comQSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 6 at 7:30 AM | globenewswire.comSee More SCYNEXIS Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SCYNEXIS? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SCYNEXIS and other key companies, straight to your email. Email Address About SCYNEXISSCYNEXIS (NASDAQ:SCYX) is a biotechnology company focused on developing and commercializing medicines for fungal infections. The company’s lead product is BREXAFEMME (ibrexafungerp), an oral, non-azole antifungal approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis and for reducing the incidence of recurrent vulvovaginal candidiasis in adult and postmenarchal adolescent females. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting glucan synthase, an enzyme required for the formation of fungal cell walls. SCYNEXIS has also investigated the medicine for other serious fungal infections, including invasive candidiasis and certain infections caused by drug-resistant fungi. The company’s development strategy has centered on addressing unmet needs where existing antifungal therapies may be limited by resistance, tolerability, drug interactions, or routes of administration. Founded in 1999 and headquartered in Jersey City, New Jersey, SCYNEXIS serves the U.S. market through its commercial activities and has pursued partnerships and regulatory development opportunities internationally. The company’s operations are primarily focused on advancing and supporting ibrexafungerp and related antifungal research.View SCYNEXIS ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
